Investor Presentaiton

29 Investor presentation Full year 2022 Human data-driven decision-making with faster timelines to enable a robust development pipeline Speed up time to reach FHD and increase number of phase 1 assets Future Research & early development trends for Novo Nordisk 2020 FHD: First human dose; RNA: Ribonucleic acid ~3x number of assets ILLUSTRATIVE 2025 • More first human doses pursued to enable a robust late-stage pipeline Around 3x faster timeline from lead candidate to first human dose First human doses with the new technologies, cell-based therapies and RNAi was in 2022 Ambition of generating first human dose projects on average per year across disease areas with the RNAi platform Novo NordiskⓇ

View entire presentation